** U.S.-listed shares of Scinai Immunotherapeutics 2F5y.F, SCNI.O rise 104% to $5.15
** Stock set for its best day on record, if gains hold
** Co says it received Italian government's clearance to potentially acquire Italian biotech firm Pincell, which is developing novel antibody to treat severe skin conditions
** Approval removes major regulatory hurdle for acquisition but does not finalize deal, SCNI says
** Scinai plans to acquire 100% of Pincell's share capital and voting rights
** Acquisition, initially agreed in March, still requires meeting additional conditions before completion, co says
** Pincell's lead drug, antibody PC111, is being developed to treat rare and severe skin disorders
** Including session's moves, SCNI up 54.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.